Hjem › Steatotisk leversykdom › New Jersey
Kliniske studier for Steatotisk leversykdom i New Jersey
6 studier for Steatotisk leversykdom søker deltakere på steder i New Jersey.
Byer i New Jersey
Offisiell studietekst (engelsk)
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Tandem Clinical Research - Freehold, Freehold
- Atlantic Health System Morristown Medical Center, Morristown
- Clinical Research of Philadelphia, Pennington
- og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Jackson
- Akero Clinical Study Site, Somers Point
- Akero Clinical Study Site, Sparta
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Jersey City
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Clinical Research Integrity (CRI) Lifetree, LLC, Marlton
- Premier Health Research, Sparta
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Freehold
- 89bio Clinical Study Site, Warren Township
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Somers Point
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06419374Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.